Imperial College London
Portrait Picture

DrJonathanKrell

Faculty of Medicine, Department of Surgery & Cancer

Clinical SL in Medical Oncology (Gynaecological Oncology)
 
 
 
//

Contact

 

j.krell

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rumford:2020:10.1038/s41598-020-60149-5,
author = {Rumford, M and Lythgoe, M and McNeish, I and Gabra, H and Tookman, L and Rahman, N and George, A and Krell, J},
doi = {10.1038/s41598-020-60149-5},
journal = {Scientific Reports},
title = {Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management},
url = {http://dx.doi.org/10.1038/s41598-020-60149-5},
volume = {10},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Although guidelines recommend BRCA testing for all women with non-mucinous epithelial ovarian cancer, there is significant variability in access to testing across the UK. A germline BRCA mutation (BRCAm) in ovarian cancer patients provides prognostic and predictive information and influences clinical management, such as the use of PARP inhibitors, which have demonstrated a progression-free survival benefit in the BRCAm cohort. Additionally, the finding of a BRCAm has significant implications for patients and their families in terms of cancer risk and prevention. We studied the impact of a newly-formed, oncologist-led ‘mainstreaming’ germline BRCA testing pathway in 255 ovarian cancer patients at Imperial College NHS Trust. Prior to the establishment of ‘mainstreaming’, uptake of germline BRCA testing was 14% with a mean turnaround time of 148.2 calendar days. The ‘mainstreaming’ approach led to a 95% uptake of germline BRCA testing and a mean turnaround time of 20.6 days. Thirty-four (13.33%) BRCAm patients were identified. At the time of data collection nine BRCAm patients had received a PARP inhibitor off-trial, three had entered a PARP inhibitor trial and 5 were receiving platinum-based chemotherapy with a plan to receive PARP inhibitor maintenance. This study provides further evidence of the impact of oncologist-led ‘mainstreaming’ programs.
AU  - Rumford,M
AU  - Lythgoe,M
AU  - McNeish,I
AU  - Gabra,H
AU  - Tookman,L
AU  - Rahman,N
AU  - George,A
AU  - Krell,J
DO  - 10.1038/s41598-020-60149-5
PY  - 2020///
SN  - 2045-2322
TI  - Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-020-60149-5
UR  - http://hdl.handle.net/10044/1/77768
VL  - 10
ER  -
Download